What PT-141 is
PT-141 is the research name for bremelanotide, a small synthetic peptide that mimics a family of brain hormones called melanocortins. Today it is mostly known as the active ingredient in Vyleesi, an injection approved for women.
The key point for men is what it does not do. Sildenafil, tadalafil and the other ED pills work in the penis, helping blood vessels relax once you are aroused. PT-141 works upstream, in the brain, where desire and arousal start. That is why it comes up when the problem is wanting sex at least as much as performing, a distinction our page on low libido or ED unpacks.
FDA status: approved for women only
The FDA approved bremelanotide as Vyleesi on June 21, 2019, according to the agency’s approval letter. The approval is narrow. The Vyleesi label covers premenopausal women with acquired, generalized hypoactive sexual desire disorder, and states plainly that it is not indicated for men, for postmenopausal women, or to enhance sexual performance.
So any use of PT-141 in men is off-label. In practice it comes from compounding pharmacies, often as part of a blend, rather than as the Vyleesi autoinjector. Off-label use is legal when a licensed clinician judges it appropriate, but it means the dose, the benefit and the risks in men rest on smaller studies rather than an FDA review.
How does it work, and what is the evidence in men?
Bremelanotide activates melanocortin receptors, mainly MC1R and MC4R at the doses used, and MC4R receptors are found throughout the central nervous system. The label says the exact way it improves desire in women is unknown, and the same honesty applies to men.
The human evidence in men is early. In a 2004 placebo-controlled study of intranasal PT-141 in healthy men and men with mild to moderate ED, doses above 7 mg produced erections significantly more often than placebo, with the first erection at about 30 minutes; flushing and nausea were the most common side effects. A 2005 crossover study of 19 men with ED found that a low PT-141 dose plus 25 mg sildenafil produced a stronger erectile response than sildenafil alone.
Both trials were small, short and sponsored by the company developing the drug, and the nasal form was never brought to market. They support the idea that PT-141 can add something when combined with a PDE5 medicine, not that it works reliably on its own in men.
Side effects: nausea and blood pressure
Nausea is the effect people notice most. In the women’s trials summarized on the Vyleesi label, 40% reported nausea, 13% needed anti-nausea medicine and 8% stopped because of it, though it usually eased by the second dose. Flushing, injection-site reactions, headache and vomiting were the other common effects.
The blood pressure effect matters more for men over 40. Each dose raised blood pressure by up to 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with a drop in heart rate of up to 5 beats per minute, and readings usually returned to baseline within 12 hours. That is why the label rules it out for uncontrolled high blood pressure or known heart disease. Our page for men on blood pressure medicines explains how that history shapes ED treatment.
Two more label points apply to anyone using bremelanotide:
- Skin darkening. Focal hyperpigmentation of the face, gums or chest was reported in 1% of women dosing up to 8 times a month, but in 38% of those dosing daily for 8 days, and it did not always fade. Frequent use raises this risk.
- Naltrexone. Bremelanotide can significantly lower the amount of oral naltrexone that reaches the blood, so men taking it for alcohol or opioid use should not combine the two.
Who should not use PT-141
PT-141 is not a fit if you have uncontrolled high blood pressure, known heart or blood vessel disease, or a high cardiovascular risk profile. It is also a poor fit if you take oral naltrexone, if you are prone to severe nausea, or if you have darker skin, which the label links to a higher chance of lasting dark patches. Because PT-141 does nothing to fix an underlying blood flow problem, it should not be used to mask ED that has not been evaluated.
If a provider does recommend it, monitoring is simple but real: a blood pressure check before starting and at follow-up, a record of how often you use it, and a report of any nausea or new dark spots on the skin. Using it less often is the main lever for most of these problems.
Chest pain, fainting or a severe headache after a dose needs 911 or an emergency room. An erection that lasts more than four hours does too, especially if PT-141 is combined with tadalafil or another ED medicine.
PT-141 in the Olympus Male blend at Ultimate Male
At Ultimate Male, PT-141 is used as one ingredient in Olympus Male, a custom compounded blend of oxytocin, PT-141 and tadalafil aimed at arousal, function and intimacy together. It is one option within the clinic’s ED medications, alongside oral pills, topical options and Trimix or Quadmix injections.
Whether a blend containing PT-141 makes sense for you is decided at a one-on-one consultation with a PA-C or MD. Blood pressure, heart history and current medicines come first, and blood tests for ED such as testosterone and glucose help show whether low desire has a hormonal or metabolic cause worth treating directly. You will hear plainly that PT-141 is off-label in men and what that means before anything is started.
